Literature DB >> 24180451

Reversal of vascular leak with imatinib.

Jurjan Aman1, Mike J L Peters, Carla Weenink, Geerten P van Nieuw Amerongen, Anton Vonk Noordegraaf.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24180451     DOI： 10.1164/rccm.201301-0136LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  10 in total

Review 1.  Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.

Authors:  Dakota Gustafson; Jason E Fish; Jeffrey H Lipton; Nazanin Aghel
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

2.  Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury.

Authors:  Alicia N Rizzo; Saad Sammani; Adilene E Esquinca; Jeffrey R Jacobson; Joe G N Garcia; Eleftheria Letsiou; Steven M Dudek
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-02       Impact factor: 5.464

Review 3.  Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome.

Authors:  Alicia N Rizzo; Jurjan Aman; Geerten P van Nieuw Amerongen; Steven M Dudek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-03-26       Impact factor: 8.311

4.  Imatinib alleviates lung injury and prolongs survival in ventilated rats.

Authors:  Yi Xin; Maurizio Cereda; Nadir Yehya; Shiraz Humayun; Paolo Delvecchio; Jill M Thompson; Kevin Martin; Hooman Hamedani; Paul Martorano; Ian Duncan; Stephen Kadlecek; Mehran Makvandi; Jacob S Brenner; Rahim R Rizi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-04-19       Impact factor: 6.011

5.  Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury.

Authors:  E Letsiou; A N Rizzo; S Sammani; P Naureckas; J R Jacobson; J G N Garcia; S M Dudek
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-12-05       Impact factor: 5.464

Review 6.  Using cultured endothelial cells to study endothelial barrier dysfunction: Challenges and opportunities.

Authors:  Jurjan Aman; Ester M Weijers; Geerten P van Nieuw Amerongen; Asrar B Malik; Victor W M van Hinsbergh
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-06-24       Impact factor: 5.464

7.  Prolonging Gastrointestinal-Stromal-Tumor-free life, an optimal suggestion of imatinib intervention ahead of operation.

Authors:  Lin-Hai Yan; Zhi-Ning Chen; Chun-Jun Li; Jia Chen; Yu-Zhou Qin; Jian-Si Chen; Wei-Zhong Tang
Journal:  J Cancer       Date:  2018-10-05       Impact factor: 4.207

8.  The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19.

Authors:  Leila Atmowihardjo; Job R Schippers; Imke H Bartelink; Pierre M Bet; Nienke van Rein; Keith Purdy; David Cavalla; Valérie Comberiati; Andrew McElroy; Sue D Snape; Harm Jan Bogaard; Leo Heunks; Nicole Juffermans; Marcus Schultz; Pieter R Tuinman; Lieuwe D J Bos; Jurjan Aman
Journal:  Trials       Date:  2022-02-16       Impact factor: 2.279

9.  Arg mediates LPS-induced disruption of the pulmonary endothelial barrier.

Authors:  Alicia N Rizzo; Patrick Belvitch; Regaina Demeritte; Joe G N Garcia; Eleftheria Letsiou; Steven M Dudek
Journal:  Vascul Pharmacol       Date:  2020-03-30       Impact factor: 5.773

10.  Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial.

Authors:  Jurjan Aman; Erik Duijvelaar; Liza Botros; Azar Kianzad; Job R Schippers; Patrick J Smeele; Sara Azhang; Imke H Bartelink; Ahmed A Bayoumy; Pierre M Bet; Wim Boersma; Peter I Bonta; Karin A T Boomars; Lieuwe D J Bos; Job J M H van Bragt; Gert-Jan Braunstahl; Lucas R Celant; Katrien A B Eger; J J Miranda Geelhoed; Yurika L E van Glabbeek; Hans P Grotjohan; Laura A Hagens; Chris M Happe; Boaz D Hazes; Leo M A Heunks; Michel van den Heuvel; Wouter Hoefsloot; Rianne J A Hoek; Romke Hoekstra; Herman M A Hofstee; Nicole P Juffermans; E Marleen Kemper; Renate Kos; Peter W A Kunst; Ariana Lammers; Ivo van der Lee; E Laurien van der Lee; Anke-Hilse Maitland-van der Zee; Pearl F M Mau Asam; Adinda Mieras; Mirte Muller; Liesbeth Neefjes; Esther J Nossent; Laurien M A Oswald; Maria J Overbeek; Carolina Pamplona; Nienke Paternotte; Niels Pronk; Michiel A de Raaf; Bas F M van Raaij; Merlijn Reijrink; Marcus J Schultz; Ary Serpa Neto; Elise M Slob; Frank W J M Smeenk; Marry R Smit; A Josien Smits; Janneke E Stalenhoef; Pieter R Tuinman; Arthur L E M Vanhove; Jessie N Wessels; Jessie C C van Wezenbeek; Anton Vonk Noordegraaf; Frances S de Man; Harm J Bogaard
Journal:  Lancet Respir Med       Date:  2021-06-17       Impact factor: 30.700
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.